Table 5. The long-term outcomes of ATL patients who developed opportunistic infections (ATL progression or ATL relapse).

	Age	Sex	Subtype	Infection	Onset	Outcome of opportunistic infection	Response of ATL	Duration of ATL disease progression	ATL progression	Clonality	sIL- 2R	Final outcome after ATL development
Previous report’s case 1 Tashiro T et al. 1992	66	F	smoldering	Cryptococcus pneumonia	Initial diagnosis	Alive	SD	16 months	Aggressive Type	n.e.	n.e.	dead (4 months)
Previous report’s case 2 Tashiro T et al. 1992	46	M	smoldering	Pneumocystis pneumonia	Initial diagnosis	Alive	SD	16 months	Aggressive Type	n.e.	n.e.	dead (3 months)
Previous report’s case 3 Tashiro T et al. 1992	55	F	carrier	Cryptococcus pneumonia	Initial diagnosis	Alive	SD	14 months	Aggressive type	n.e.	n.e.	alive (12 months)
Previous report’s case 4 Tanaka T et al. 2015	67	M	carrier	CMV enteritis	Initial diagnosis	Alive	n.d.	n.d.	Smoldering type	n.e.	4304	n.d.
Previous report’s case 5 Tanaka T et al. 2015	78	F	carrier	Pneumocystis pneumonia, herpes infection	Initial diagnosis	Dead	n.d.	n.d.	Smoldering type	n.e.	14058	dead (4 months)
Present case 3	65	M	Chronic	Cryptococcus pneumonia, meningitis	Initial diagnosis	Alive	SD	226 days	Acute type	monoclonality	2280	dead (79 days)
Present case 6	56	F	acute	CMV pneumonia	During treatment	Alive	CR	213 days	Relapse after self remission	biclonality	9790	dead (27 days)
Present case 7	67	M	acute	CMV pneumonia	During treatment	Alive	PR	133 days	Relapse after self remission	monoclonality	36200	dead (133 days)
Present case 11	54	M	chronic	Pneumocystis pneumonia	Initial diagnosis	Alive	PR	194 days	Acute type	monoclonality	14500	alive (194 days)
Present case 12	78	M	smoldering	Pneumocystis pneumonia	Initial diagnosis	Alive	SD	153 days	Acute type	monoclonality	4520	dead (153 days)